Trial · NCT04377620
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 13 of 13
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage of Participants Who Have Died Due to Any Cause | Study start to Day 29 | To evaluate the 28-day mortality rate of ruxolitinib 5 mg BID + SoC therapy and ruxolitinib 15 mg BID + SoC compared with placebo + SoC therapy, in participants with COVID-19-associated ARDS who require mechanical ventilation. |
| Secondary | Number of Ventilator Free Days | Study start to Day 29 | Number of days participant did not require mechanical ventilation |
| Secondary | Number of ICU Free Days | Study start to Day 29 | Number of days participant is out of the ICU |
| Secondary | Oxygen Free Days | Study start to Day 29 | Number of days participant did not receive supplemental oxygen |
| Secondary | Vasopressor Free Days | Study start to Day 29 | Number of days without use of vasopressor therapy |
| Secondary | Hospital Free Days | Study start to Day 29 | Number of days Partcipant is out of the hospital |
| Secondary | Percentage of Participants With at Least 2-point Improvement in the COVID-19 Ordinal Scale | Study start to Days 15 and 29 | Participants with at least 2-point improvement at Day 15 and 29 based on participant state. The scale ranges from 0-8 with 0 being no clinical or virological evidence of infection and 8 being dead |
| Secondary | Percentage of Participants With at Least 1-point Improvement in the COVID-19 Ordinal Scale | Study start to Days 15 and 29 | Participants with at lest 1-point improvement in clinical status at Days 15 and 29 based on participant state. The scale ranges from 0-8 with 0 being no clinical or virological evidence of infection and 8 being dead |
| Secondary | Time to Improvement From Baseline Category to Earliest 1-point Improvement in the COVID-19 Ordinal Scale | Study Start to Day 29 | TIme to improvement compared to baseline. The scale ranges from 0-8 with 0 being no clinical or virological evidence of infection and 8 being dead |
| Secondary | Percentage of Participants With the COVID-19 Ordinal Scale Reported | Study start to Day 29 | Clinical status of participant at Day 29 based on participant state. The scale ranges from 0-8 with 0 being no clinical or virological evidence of infection and 8 being dead |
| Secondary | Change in the COVID-19 9-point Ordinal Scale | Study start to Days 15 and 29 | Change in the Clinical status of participant at Days 15 and 29 based on participant state. The scale ranges from 0-8 with 0 being no clinical or virological evidence of infection and 8 being dead |
| Secondary | Change in SOFA Score | from baseline to Days 3, 5, 8, 11, 15, and 29 | Sequential Organ Failure Assessment (SOFA) score is a scoring system to determine the extent of a person's organ function or rate of failure. The score is based on 6 different scores, 1 each for the respiratory, cardiovascular, hepatic, coagulation, renal, and neurological systems. Each system gets a score from 0 (normal) to 4 (abnormal) and the sum of each score defines the final SOFA score, which 24 is the maximum score (high risk of morality) and 0 is the minimum score (low risk of mortality). |
| Secondary | Number and Percentage of Participants With Treatment-related Side Effects and Serious Adverse Events | Study start to Day 29 | Treatment-emergent AEs are judged as related by the investigator or have a missing causality. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04377620/registered